Acute Myeloid Leukemia (AML): Prognostics and Tailored Therapy
Description: Farhad Ravandi-Kashani, MD, of MD Anderson Cancer Center, discusses current guidelines and best practices regarding AML prognostics, genetic mutations often found in patients with AML, and new targeted therapies currently being developed.
• Communicate recent updates to the NCCN guidelines regarding AML prognostics and treatment
• Discuss how best to apply this new information to the clinical management of patients with AML
• Describe strategies for the optimal management of biopsy specimens to allow for additional subsequent evaluations that further inform clinical decision making